<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00858767</url>
  </required_header>
  <id_info>
    <org_study_id>08-3-064</org_study_id>
    <nct_id>NCT00858767</nct_id>
  </id_info>
  <brief_title>Arabic Gum-Absorption Study</brief_title>
  <official_title>Comparison of Absorption and Efficacy of 3 Different Menaquinone-7 Delivery Systems; Casein Powder, Arabic Gum Powder, or Linseed Oil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies have indicated that menaquinone-7 (MK-7) is the most effective form of
      vitamin K. The Japanese soya product natto is one of the richest food sources of MK-7, but
      its taste is not appreciated by the Western society. For this reason, the active biological
      compound has been manufactured as enriched oil or casein (≈80% of proteins in cow's
      milk)-enriched powder. However, cow's milk allergy is the most common cause of food allergy
      affecting a minimum of 2-3% of infants. The investigators will therefore compare this
      protein-delivery system to an alternative delivery system (Arabic gum; 98% polysaccharides).
      To compare the difference between powder and oil as MK-7 delivery vehicle, the investigators
      will also test the efficacy of enriched linseed oil.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum level menaquinone-7</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma level of biochemical markers carboxylated matrix-Gla protein, undercarboxylated matrix-Gla protein, carboxylated osteocalcin, undercarboxylated osteocalcin</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Bioavailability</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 casein capsules per day existing of 90 µg menaquinone-7 per day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 arabic gum capsules per day existing of 90 µg menaquinone-7 per day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 linseed capsules existing of 90 µg menaquinone-7 per day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>menaquinone-7 from casein capsules</intervention_name>
    <description>90 µg menaquinone-7 daily during 8 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>menaquinone-7 from arabic gum capsules</intervention_name>
    <description>90 µg menaquinone-7 daily during 8 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>menaquinone-7 from linseed oil capsules</intervention_name>
    <description>90 µg menaquinone-7 daily during 8 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women aged between 20 and 40 y

          -  Normal body weight and height (BMI &lt;30 kg/m2)

          -  Stable body weight (weight gain or loss &lt;3 kg in past 3 mo)

          -  Caucasian race

          -  Written consent to take part in the study

          -  Low vitamin K status

        Exclusion Criteria:

          -  (A history of) metabolic or gastrointestinal diseases

          -  Chronic degenerative and/or inflammatory diseases

          -  Abuse of drugs and/or alcohol

          -  Use of corticosteroids

          -  Use of oral anticoagulants

          -  (A history of) soy allergy

          -  Use of vitamin K-containing multivitamins or vitamin K supplements

          -  Anaemia

          -  Blood donation or participation in another study within one month before the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cees Vermeer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VitaK /University of Maastricht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VitaK BV /University of Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>PO Box 616</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2009</study_first_submitted>
  <study_first_submitted_qc>March 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2009</study_first_posted>
  <last_update_submitted>December 15, 2010</last_update_submitted>
  <last_update_submitted_qc>December 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. C. Vermeer</name_title>
    <organization>VitaK BV</organization>
  </responsible_party>
  <keyword>vitamin K2</keyword>
  <keyword>absorption</keyword>
  <keyword>efficacy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caseins</mesh_term>
    <mesh_term>Vitamin K 2</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin MK 7</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

